Delivery Order SPE2DB22D3501-SPE2DB25FWB74
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) with a ceiling value of $1,722.87. This firm fixed-price delivery order, awarded on July 30, 2025, with an ultimate completion date of July 31, 2025, represents a non-competitive award under an existing contract vehicle. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, which serves as AmerisourceBergen's corporate headquarters and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,914.29 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count packaging) on August 26, 2025, with an ultimate completion date of August 27, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 8, 2025, with a ceiling value of $3,831.81 and an ultimate completion date of August 11, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $48,927.46 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) on April 23, 2025, with an ultimate completion date of April 24, 2025. This firm fixed price contract represents a non-competitive delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count units) valued at $7,179.96. This firm fixed-price, non-set-aside contract was awarded on July 31, 2025, with an ultimate completion date of August 1, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a delivery order, this award represents a single fulfillment action under a larger contracting vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count supply) on August 18, 2025, with a ceiling value of $10,325.86. The contract is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. This delivery order represents a single transaction...
- The Defense Logistics Agency awarded a $22,655.56 delivery order to AmerisourceBergen Drug Corp on June 10, 2025, for the supply of Gemtesa 75 mg tablets (30-count units). This non-set-aside, competitively awarded contract represents a firm fixed-price delivery order with an ultimate completion date of June 11, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's broader pharmaceutical supply relationship with the...
- The Defense Logistics Agency awarded a delivery order valued at $6,864.48 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count supply) with an ultimate completion date of August 14, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a single delivery order fulfilling federal pharmaceutical procurement needs. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed price contract valued at $43,743.38. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of September 17, 2025. The contract is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as...
- The Defense Logistics Agency awarded a delivery order valued at $22,337.44 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count units). This firm fixed-price contract, issued on July 30, 2025, represents a non-competitive, non-set-aside award with an ultimate completion date of July 31, 2025. The pharmaceutical products will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWB74Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,385.39 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on June 17, 2025, with an ultimate completion date of June 18, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award for pharmaceutical supply to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's prime Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to military healthcare systems worldwide. The Gemtesa order represents one of numerous delivery orders placed under this contract vehicle, demonstrating the company's role as a critical vendor for the Defense Health Agency and other federal healthcare systems requiring specialty medications and pharmaceutical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.4k | 6/17/25 |